project on lupin phrma
TRANSCRIPT
INDEX
S.NO CONTENT PAGE NO
1 COMPANY OVERVIEW 3
2 PRODUCT OVERVIEW 6
3 FACTORS AFFECTING SUPPLY
8
4 FACTORS AFFECTING DEMAND
10
5 MARKET SURVEY 12
6 RESPONSE OF CONSUMER 13
7 OBSERVVATION 14
8 DEMAND SCHEDULE 15
9 TYPE OF COMPETITION 16
10 FORM OF MARKET STRUCTURE
17
11 SHORT RUN EQUILIBRIUM 18
12 LONG RUN EQUILIBRIUM 19
13 LEVEL OF BARRIERS 20
14 AFFECT ON PRICE STRATEGY
22
15 FINANCIAL STATEMENT 23
16 CSR 29
17 BIBLIOGRAPHY 34
Company Overview
Date of Establishment 1983
Revenue 580.952 ( USD in Millions )
Market Cap 161393.894597 ( Rs. in Millions )
BnCorporate Address 159 C S T Road,KalinaSantacruz (East), Mumbai-400098, Maharashtrawww.lupinworld.com
Management Details Chairperson - DeshBandhu Gupta MD - Kamal K SharmaDirectors - D K Contractor, DeshBandhu Gupta, K U Mada, K V Kamath, K V Kamoth, Kamal K Sharma, M D Gupta, Marc Desaedeleer, Nilesh Gupta,
R A Shah, R V Satam, Richard Zahn, Sunil Nair, Vijay Kelkar, Vinita Gupta
Business operationBackground
Pharmaceuticals & Drugs Lupin is a transnational company engaged in development of APIs, generic and branded formulations.It is the largest manufacturer of Tuberculosis drugs in the world. It has onshore and offshore presence of its products in 70 countries.
Its manufacturing unit is located in Goa, Tarapur, Ankleshwar, Jammu, Mandideep, Indore,
Key excutive
S.No Name Designation
1 DeshBandhu Gupta Chairman
3 Kamal K Sharma Managing Director
2 R V Satam Company Secretary
4 D K Contractor Director
5 Vinita Gupta Director
6 K U Mada Director
7 R A Shah Director
8 M D Gupta Executive Director
9 Nilesh Gupta Executive Director
10 Vijay Kelkar Additional Director
11 K V Kamoth Additional Director
12 Richard Zahn Additional Director
13 K V Kamath Independent Director
14 Vijay Kelkar Independent Director
15 Richard Zahn Independent Director
INTRODUCTION OF LUPIN PHARMAAbout Lupin
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company’s R&D endeavors have resulted in significant progress in its NCE program. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.
Our Drugs and products reach over 70 countries in the world. Today, Lupin has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 8th by prescriptions & growing at 50 %) and Japan (ranked 7th and growing at 23%). The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS - March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at 36 % YoY - IMS)
For the financial year ended March 2009, Lupin's Consolidated Revenues and Profit after Tax were Rs.39,145 million (US$ 851 million) and Rs. 5015 million (US$ 109 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visithttp://www.lupinpharmaceuticals.com.
Lupin PharmaThe Company’s concerted focus on the semi-acute therapy is the crux of the Lupin division, which has enabled the Company to attain market leadership in the Anti-TB segment of IPM. In a Rs.3,162mn Anti-TB market, Lupin commands 48% of the market share. As market leaders in this space, Lupin has embarked on an effort which would redefine the treatment guidelines based on conditions existing in India under the aegis of RIETT-Redefining Indian Expertise Based Tuberculosis Treatment.
Key Products : LupinPharma
Company Sales(Rs.Million)Current
PriceChange
(%)P/E Ratio
MarketCap.
(Rs.Million)
52-WeekHigh/Low
Sun Pharma 38615.50 1546.05 0.03 29.99 320119.09 1846/1070
Cipla 49606.00 316.75 0.06 23.49 254164.76 363/211
Dr Reddy's 41589.00 1289.90 -1.59 26.16 221305.65 1335/598
Ranbaxy Labs. 47802.86 422.90 1.54 7.89 175208.31 538/217
Glaxosmithkline
Phar18707.67 2038.00 -0.30 32.03 173149.91 2271/1086
Lupin 28985.60 1815.60 0.12 24.87 161393.89 1844/755
Cadila Healthcare 16985.00 612.00 2.84 24.21 121845.84 838/188
ProductTherapeutic segment
Product Rank in the relevant segment
R-Cinex Anti-TB 1AKT Anti-TB 1Akurit Anti-TB 1R-CIN Anti-TB 1G-CIN Gemifloxacin 1Combutol Ethambutol& Comb. 1Pyzina Pyrazinamide Plain 2
Piramal Healthcare 23162.60 500.65 -0.34 23.69 104997.75 600/250
Divi'S Lab 11905.60 721.00 4.42 34.04 91238.92 728/452
GlenmarkPharma 8545.59 271.45 3.84 44.79 70546.36 304/199
Biocon 9123.37 286.55 1.00 22.85 56740.00 311/164
Jubilant Life 24285.34 344.00 1.79 14.78 53659.62 373/155
AurobindoPharma 27948.30 882.60 2.66 10.01 48392.67 990/326
TorrentPh 11848.92 538.90 1.27 21.71 45025.94 555/164
Aventis Pharma 9744.06 1873.00 1.08 27.89 42675.74 1968/1030
Matrix Laboratories 15021.32 209.35 0.00 18.90 32729.53 227/165
Pfizer 8310.44 1050.00 0.14 22.30 31288.75 1125/711
Ipca Laboratories 12956.40 244.05 -1.09 17.19 30899.92 304/85
Ster.Biot 11783.81 112.00 0.81 16.16 27796.84 146/90
AstrazenecaPharm
a3965.06 841.00 1.41 39.15 20732.50 1109/570
Fresenius
KabiOncol2620.83 129.05 3.16 53.38 19794.28 163/42
SunPhaAdv 351.42 93.15 0.22 0.00 19251.47 105/57
Novartis 5994.80 611.15 3.22 16.32 18923.99 633/385
DishmanPharma 4158.85 221.90 0.29 21.25 17854.24 275/136
Wyeth 2863.60 785.00 1.16 29.88 17630.77 850/500
FDC 5763.62 91.50 1.95 13.60 16718.50 96/37
Strides Arcolab 7694.42 346.40 -3.27 16.57 15587.78 371/98
Abbott India 7945.57 1072.00 -2.27 19.83 15000.37 1210/415
Unichem Lab 6568.67 403.40 1.34 10.75 14357.19 453/189
Wockhardt 15038.91 121.10 0.67 0.00 13165.14 201/107
Solvay Pharma 2417.26 2519.95 3.81 28.12 12257.40 3600/650
PlethicoPharma 4721.43 351.70 0.03 15.41 11977.84 405/151
Panacea Biotec 7734.17 173.95 2.72 14.15 11319.82 248/100
Merck 4731.10 635.00 1.19 14.42 10416.94 687/371
Orchid Chemicals 11914.40 140.25 2.86 0.00 9604.78 239/78
Nectar Lifesciences 7279.68 37.85 0.00 10.70 8488.28 44/15
JB Chem&Pharma 6767.61 81.10 1.31 6.69 6753.75 96/37
Elder Pharma 6200.22 368.95 5.28 11.96 6608.61 408/218
Shilpa Medicare 1359.55 297.40 1.47 13.59 6455.28 363/64
Alembic 10940.85 47.05 1.62 29.89 6181.79 56/35
Indoco Remedies 3506.35 400.95 0.14 11.69 4919.60 442/148
NatcoPharma 2696.92 162.00 2.11 9.72 4465.67 184/71
Bliss GVS 1329.56 42.60 2.40 10.46 4290.90 51/15
Parenteral Drugs 2260.74 193.00 -2.03 14.25 3821.82 255/57
Zenotech Lab. 60.23 112.50 1.35 0.00 3821.65 139/93
Fulford India 1947.00 990.15 1.59 24.25 3801.14 1150/436
Morepen Labs 1641.04 7.90 2.33 0.00 3472.66 12/7
Ankur Drugs 9653.21 183.40 4.80 3.78 3384.78 251/100
Suven Life
Sciences1400.11 28.35 3.09 45.78 3204.75 37/18
Piramal Life
Science21.30 130.50 4.99 0.00 3163.60 152/50
Sequent Scientific 1060.62 139.95 0.14 26.57 3065.44 164/35
Zandu Realty 877.46 3540.00 -0.65 8.66 2873.40 12800/2513
Shasun Chemicals 4708.34 58.50 2.45 22.60 2758.73 72/18
TTK Healthcare 2196.47 342.00 -2.56 29.87 2725.86 435/101
Surya Pharma 7229.24 172.85 3.01 3.25 2427.79 196/75
Alchemist 3864.66 185.00 0.57 13.26 2252.43 216/82
Twilight Litaka Phar 3704.43 107.25 3.08 6.63 2214.32 132/33
Venus Remedies 2640.94 266.50 3.11 4.83 2194.75 312/182
Ajanta Pharma 3194.77 183.30 2.75 7.32 2088.80 212/73
Themis Medicare 1998.98 245.80 3.47 10.58 1912.40 301/60
Granules India 2538.74 96.50 1.85 7.94 1900.42 115/52
Amrutanjan Health 906.60 613.00 0.14 14.23 1854.81 1345/324
IndSwiLab 5834.95 66.50 2.23 3.77 1811.80 80/34
Phaarmasia 111.00 253.00 -4.99 0.00 1727.22 344/253
SMS Pharma 2445.92 167.95 2.41 71.17 1642.49 190/109
MarksansPharma 1995.30 4.35 2.35 707.32 1563.18 8/4
Vivimed Labs 1514.89 156.75 1.59 12.96 1537.58 175/65
Jupiter Bioscience 1429.28 81.95 0.43 4.90 1510.29 105/52
Aarti Drugs 3765.03 112.25 3.08 5.62 1318.62 128/48
Anu's Labs 1597.09 5.90 8.66 7.67 1311.45 27/5
Kilitch Drugs 1290.12 100.00 3.31 10.84 1277.97 157/59
Sharon Bio-
Medicine4197.91 115.00 2.68 5.30 1182.37 144/42
Kopran 1186.42 32.10 4.05 11.60 1144.62 37/9
IndSwiLtd 5870.55 29.50 1.03 3.03 1085.61 37/16
Wanbury 1672.88 72.45 1.26 0.00 1051.02 96/44
AnuhPharma 1205.13 377.85 2.29 7.97 1028.41 465/172
RPG Life Sciences 1392.43 70.80 5.12 9.40 1014.89 92/26
Bharat 71.08 18.75 3.02 0.00 785.88 26/17
Immunological
Ambal Sarabhai 625.10 10.12 1.30 4.14 765.57 17/10
Hester Biosciences 301.60 136.50 -0.73 12.14 713.79 156/76
Albert David 2056.92 124.05 1.39 6.80 698.27 143/62
Syncom Healthcare 605.65 39.20 1.29 17.07 677.25 162/39
BafnaPharma 457.99 43.60 3.20 14.19 675.21 45/19
Adinath Bio-Lab 218.18 2.86 -4.35 34.79 660.02 21/3
Lyka Labs 1520.75 29.25 2.63 26.45 615.03 41/17
DIL 17.68 263.00 5.05 7.50 574.10 309/146
JagsonpalPharma 1361.98 21.20 6.53 5.70 521.34 27/11
Neuland Lab. 3067.22 94.95 2.10 0.00 501.87 160/92
HiranOrgochem 1885.67 9.55 1.38 0.00 494.58 13/4
Kerala Ayurveda 179.85 45.35 0.00 0.00 478.70 66/30
Gufic Biosciences 515.76 6.13 3.03 36.13 460.23 11/4
Arvind Remedies 2178.88 1.73 5.49 5.75 426.48 3/1
Smruthi Organics 729.54 105.25 0.19 7.22 400.81 132/38
AhlconParenterals 378.30 54.25 0.00 9.19 390.61 58/22
Lincoln Pharma 1140.18 32.50 2.52 4.58 358.55 39/19
Celestial Biolabs 192.51 31.55 5.34 5.96 352.90 45/14
Rubra Medicaments 10.21 61.85 4.92 0.00 322.36 59/10
Syncom
Formulations575.64 26.50 4.33 6.47 315.22 34/15
Alpa Lab 1201.01 14.65 -0.68 38.94 310.35 20/11
Elder 508.08 74.35 -1.20 0.00 301.00 111/26
Maxter
As the face of Lupin in the critical care segment and Anti- Infectives, Maxter Division emulates the Company’s objective of ‘saving more lives’. As a spin-off from Endeavour, the division was launched in 2006-07. The inception of Maxter has empowered Lupin to tap unexplored opportunities in chosen therapeutic area, with an unwavering focus. This division focuses on giving the best therapeutic care in the critical care segment. It reaches out to interventionists and super-specialty doctors and has also ventured into the field of wound management.
Key Products :Maxter
Product Therapeutic segmentProduct Rank in the relevant segment
Merotrol Meropenem 1
Tazar Piperacillin + Tazobactam
1
Ceff Cephalexin Oral Solids
3
Cetil Cefuroxime Oral Solids
5
Cefantral CefotaximeInjectibles 9
PRODUCTS OF LUPIN PHARMA
LupinPharma
Brand Name Molecule Therapy Segment
AKT 2Each Kit contains RIFAMPICIN - 450 MG+ ISONIAZID - 300 MG
TUBERCULOSTATIC
AKT3Each Kit contains RIFAMPICIN - 450 MG + ISONIAZID - 300 MG+ ETHAMBUTOL - 800 MG
TUBERCULOSTATIC
AKT4 Each Kit contains RIFAMPICIN - TUBERCULOSTATIC
450 MG + ISONIAZID - 300 MG + ETHAMBUTOL - 800 MG + PYRAZINAMIDE - 1500 MG
AKT FD
Each tablet contains RIFAMPICIN - 150 MG+ISONIAZID -100 MG + ETHAMBUTOL - 267 MG + PYRAZINAMIDE - 500 MG
TUBERCULOSTATIC
AKURIT4
Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID - 75 MG +ETHAMBUTOL - 275 MG + PYRAZINAMIDE - 400 MG
TUBERCULOSTATIC
AKURIT3
Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID - 75 MG + ETHAMBUTOL -275 MG
TUBERCULOSTATIC
AKURITEach tablet contains RIFAMPICIN - 150 MG + ISONIAZID -75 MG
TUBERCULOSTATIC
AKURIT Z KID
Each tablet contains RIFAMPICIN - 60 MG + ISONIAZID -30 MG + PYRAZINAMIDE -150 MG
TUBERCULOSTATIC
AKURIT KIDEach tablet contains RIFAMPICIN - 60 MG + ISONIAZID - 30 MG
TUBERCULOSTATIC
COMBUTOL 200
Each tablet contains ETHAMBUTOL - 200 MG
TUBERCULOSTATIC
COMBUTOL 400
Each tablet contains ETHAMBUTOL - 400 MG
TUBERCULOSTATIC
COMBUTOL 600
Each tablet contains ETHAMBUTOL - 600 MG
TUBERCULOSTATIC
COMBUTOL 800
Each tablet contains ETHAMBUTOL - 800 MG
TUBERCULOSTATIC
COMBUTOL 1000
Each tablet contains ETHAMBUTOL - 1000 MG
TUBERCULOSTATIC
COMBUNEXEach tablet conatins ETHAMBUTOL - 800 MG + ISONIAZID - 300 MG
TUBERCULOSTATIC
PYZINAKIDEach tablet contains PYRAZINAMIDE - 300 MG
TUBERCULOSTATIC
PYZINA 500Each tablet contains PYRAZINAMIDE - 500 MG
TUBERCULOSTATIC
PYZINA 750Each tablet contains PYRAZINAMIDE - 750 MG
TUBERCULOSTATIC
PYZINA 1000Each tablet contains PYRAZINAMIDE - 1000 MG
TUBERCULOSTATIC
R-CIN 150 MGEach capsule contains RIFAMPICIN - 150 MG
TUBERCULOSTATIC
R-CIN 300 MGEach capsule contains RIFAMPICIN - 300 MG
TUBERCULOSTATIC
R-CIN 450 MGEach capsule contains RIFAMPICIN - 450 MG
TUBERCULOSTATIC
R-CIN 600 MGEach capsule contains RIFAMPICIN - 600 MG
TUBERCULOSTATIC
R-CIN SYRUPEach 5ml containsRIFAMPICIN - 100 MG
TUBERCULOSTATIC
R-CINEX 450 MG
Eah tablet contains RIFAMPICIN - 450 MG+ ISONIAZID - 300 MG
TUBERCULOSTATIC
R-CINEX 600 MG
Each tablet contains RIFAMPICIN - 600 MG +ISONIAZID - 300 MG
TUBERCULOSTATIC
R-CINEX KIDEah tablet containsRIFAMPICIN - 100 MG + ISONIAZID - 100 MG
TUBERCULOSTATIC
R-CINEX ZEah tablet contains RIFAMPICIN - 225 MG + ISONIAZID - 150 MG + PYRAZINAMIDE - 750MG
TUBERCULOSTATIC
RCINEX EEah tablet contains RIFAMPICIN - 450+ ISONIAZID - 300 MG + ETHAMBUTOL - 800 MG
TUBERCULOSTATIC
RCINEX EZ Eah tablet contains RIFAMPICIN TUBERCULOSTATIC
- 225 MG + ISONIAZID - 150 MG +ETHAMBUTOL - 400 MG + PYRAZINAMIDE - 750 MG
RCINEX DTEah tablet contains RIFAMPICIN - 100 MG + ISONIAZID - 50 MG
TUBERCULOSTATIC
RCINEX Z KIDEah tablet contains RIFAMPICIN - 100 MG + ISONIAZID - 50 MG + PYRAZINAMIDE - 300 MG
TUBERCULOSTATIC
RINIZIDE FORTE DT
Eah tablet contains RIFAMPICIN -150 MG + ISONIAZID -100 MG + PYRAZINAMIDE -500 MG
TUBERCULOSTATIC
ETHIDE TABLETS
Eah tablet contains ETHIONAMIDE - 250 MG
TUBERCULOSTATIC
PETHIDEEah tablet contains PROTHIONAMIDE - 250 MG
TUBERCULOSTATIC
Q-PAS PARA-AMINOSALICYLIC ACID TUBERCULOSTATIC
CYCLORIN 250 MG
Each capsule contains CYCLOSERINE - 250 MG
TUBERCULOSTATIC
EFFICIN 500MG
Each vial contains KANAMYCIN - 500 MG
TUBERCULOSTATIC
EFFICIN 750MG
Each vial contains KANAMYCIN - 750 MG
TUBERCULOSTATIC
EFFICIN 1000MG
Each vial contains KANAMYCIN - 1000 MG
TUBERCULOSTATIC
RIBUTINEah tablet contains RIFABUTIN - 150 MG
HIV-TUBERCULOSTATIC
BENZEach pearl contains BENZONATATE - 100 MG
COUGH SUPRESSANT
E-CEF 125 MG
Each vial contains CEFTRIAXONE - 125 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
E-CEF 250 MG
Each vial contains CEFTRIAXONE - 250 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
E-CEF 500 MG
Each vial contains CEFTRIAXONE - 500 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
E-CEF 1000 MG
Each vial contains CEFTRIAXONE - 1000 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
ECEF ODEach vial contains CEPHALEXIN - 250 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
ECEF S 1.5Each vial contains CEFTRIAXONE+SULBACTAM 1500 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
ECEF S 750MG
Each vial contains CEFTRIAXONE+SULBACTAM 750 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
ECEF S 375 MG
Each vial contains CEFTRIAXONE+SULBACTAM 375 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
GCIN Eah tablet contains GEMIFLOXACIN - 320 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
LCIN 750Eah tablet contains LEVOFLOXACIN - 750 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
LCIN OZEah tablet contains LEVOFLOXACIN - 250 MG + ORNIDAZOLE - 500 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
LCIN IVEach vial contains LEVOFLOXACIN - 500MG/100ML
ANTI-INFECTIVES/ ANTI-BIOTICS
RTIST 300MGEach capsule contains CEFDINIR - 300 MG
ANTI-INFECTIVES/ ANTI-BIOTICS
RTIST SUSPEach 5ml contains CEFDINIR - 125MG/5ML
ANTI-INFECTIVES/ ANTI-BIOTICS
NECTERA POWDER
Each 3gm powder contains 500mg COLOSTRUM (28%IgG) - 90gm TIN
NUTRACEUTICAL
DEFNALONE 1MG
Each tablet conatins DEFLAZACORT -1 MG
GLUCOCORTICOID / STERIOD
DEFNALONE 6MG
Each tablet contains DEFLAZACORT - 6 MG
GLUCOCORTICOID / STERIOD
DEFNALONE 24MG
Each tablet contains DEFLAZACORT - 24 MG
GLUCOCORTICOID / STERIOD
DEFNALONE 30MG
Each tablet contains DEFLAZACORT - 30 MG
GLUCOCORTICOID / STERIOD
LUPIGEST 100
NATURAL PROGESTERONE - 100 MG
HormonesLUPIGEST 200
NATURAL PROGESTERONE - 200 MG
YAMINIDROSPIRENONE - 3 MG +ETHINYLESTRADIOL - 0.03 MG Hormones
MEFNIL MIFEPRISTONE - 200 MG
MISONIL -200 MCG
MISOPROSTOL - 200 MCG
HormonesMISONIL -25 MCG
MISOPROSTOL - 25 MCG
FASTRACE PREGNANCY KIT Pregnancy Detection
OVIPHENE-25 CLOMIFENE CITRATE - 25 MGHormones
OVIPHENE-50 CLOMIFENE CITRATE - 50 MG
LUPI-HMG 75IU
HUMAN MENOPAUSAL GONADOTROPIN INJ. 75 I.U.
HormonesLUPI-HMG 150IU
HUMAN MENOPAUSAL GONADOTROPIN INJ. 150 I.U.
LUPI-FSH 75IU
FOLLICLE STIMULATING HORMONE INJ. 75 I.U.
HormonesLUPI-FSH 150IU
FOLLICLE STIMULATING HORMONE INJ. 150 I.U.
LUPI-HCG 2000
HUMAN CHORIONIC GONADOTROPIN INJ. 2000 I.U.
HormonesLUPI-HCG 5000
HUMAN CHORIONIC GONADOTROPIN INJ. 5000 I.U.
LUPI-HCG 10000
HUMAN CHORIONIC GONADOTROPIN INJ.10000 I.U.
MindVision
Brand Name
Molecule Therapy Segment
Stalopam Escitalopram 5mg Antidepressant
Escitalopram 10mg Antidepressant
Escitalopram 20mg Antidepressant
Stalopam PlusEscitalopram 10mg + Clonazepam 0.5mg
Antidepressant
Citistar Citicoline 500mg Nootropic
Citicoline (250mg/ml) Nootropic
Citicoline 500mg (250mg/ml) Nootropic
Citicoline 1000 mg Sustained Release tablets
Nootropic
Epilive Levetiracetam 250mg Tablets Antiepileptics
Levetiracetam 500mg Tablets Antiepileptics
Levetiracetam 750mg Tablets Antiepileptics
Lovax Oxcarbazepine 150mg Antiepileptics
Oxcarbazepine 300mg Antiepileptics
Oxcarbazepine 600mg Antiepileptics
Lovax ODOxcarbazepine 300mg Extended Release
Antiepileptics
Oxcarbazepine 600mg Antiepileptics
Extended Release
Dayo OD Divalproex 250mg Antiepileptics
Divalproex 500mg Antiepileptics
Divalproex 750mg Antiepileptics
Pregadoc Pregabaline 75mg Agent for neurpathic pain
Pregabaline 150mg Agent for neurpathic pain
Pregadoc MPregabalin 75mg + Mecobalamin 750mcg Capsules
Agent for Neuropathic Pain
Pregabalin 150mg + Mecobalamin 750mcg Capsules
Agent for Neuropathic Pain
Amigold Amisulpride 50mg Antipsychotic
Amisulpride 100mg Antipsychotic
Amisulpride 200mg Antipsychotic
Jolyon - MD Olanzepine 5mg Antipsychotic
Olanzepine 7.5mg Antipsychotic
Olanzepine 10mg Antipsychotic
Olanzepine 15mg Antipsychotic
Arzu Aripiprazole 15mg Antipsychotic
Aripiprazole 10mg Antipsychotic
Aripiprazole 30mg Antipsychotic
Placidin Quetiapine 100mg Antipsychotic
Quetiapine 200mg Antipsychotic
Quetiapine 25mg Antipsychotic
PlaciDox Diazepam 10mg Tranquilizers
Diazepam 2mg Tranquilizers
Diazepam 5mg Tranquilizers
DULOT Duloxetine 20mg Antidepressant
Duloxetine 30mg Antidepressant
Anxicalm Alprazolam 0.25mg Tranquilizers
Alprazolam 0.5mg Tranquilizers
Goodnoct XR Zolpidem 6.25mg Extended Release Tablets
Hypnotic
Zolpidem 12.5mg Extended Release Tablets
Hypnotic
Tolifast Tolperisone 150mg Tablets Muscle Relaxant
Movexol Pramipexole 0.25mg Tablets Drug for Parkinson's Disease
Pramipexole 0.5mg Tablets Drug for Parkinson's Disease
Pramipexole 1mg Tablets Drug for Parkinson's Disease
Fibril Ispaghula husk Laxatives
Fibril SF Ispaghula husk Laxatives
Ribavin 200 mg Ribavirin 200mg Hepatitis C
Ribavirin 50mg Hepatitis C
Alzidoc Donepezil 5mg Tablets Drug for Alzheimer's Disease
Donepezil 10 mg Tablets Drug for Alzheimer's Disease
Restfull Flupentixol 0.5mg + Melitracen 10mg Tablets
Anxiolytic
Edastar Edaravone injection 1.5 mg/mL(20 mL)
Other CNS drugs
PinnacleFor more details on the below given information, kindly visit www.epinnacleworld.com
Brand Name Molecule Therapy Segment
TONACT 5 Atorvastatin Cholesterol Reducer
TONACT 10 Atorvastatin Cholesterol Reducer
TONACT 20 Atorvastatin Cholesterol Reducer
TONACT 40 Atorvastatin Cholesterol Reducer
TONACT 80 Atorvastatin Cholesterol Reducer
TONACT PLUS Atorvastatin + Niacin Cholesterol Reducer
TONACT FORTE Atorvastatin + Niacin Cholesterol Reducer
TONACT 10MG EZ Atorvastatin +Ezetimibe Cholesterol Reducer
TONACT 20mg EZ Atorvastatin +Ezetimibe Cholesterol Reducer
TONACT TG Atorvastatin + Fenofibrate Cholesterol Reducer
TONACT 10 MP Atorvastatin Cholesterol Reducer
TRITONACTAtorvastatin + Fenofibrate + Ezetimibe
Cholesterol Reducer
TONACT-TM Atorvastatin + TelmisartanCholesterol Reducer + Anti-Hypertensive
RAMISTAR 1.25 Ramipril Anti-Hypertensive
RAMISTAR 2.5MG Ramipril Anti-Hypertensive
RAMISTAR 5MG Ramipril Anti-Hypertensive
RAMISTAR 10MG Ramipril Anti-Hypertensive
RAMISTAR A 2.5 Ramipril + Amlodipine Anti-Hypertensive
RAMISTAR H 2.5 Ramipril +Hctz Anti-Hypertensive
RAMISTAR H 5 Ramipril +Hctz Anti-Hypertensive
RETORLIX 5 Torsemide Diuretic
RETORLIX 10 Torsemide Diuretic
RETORLIX 20 Torsemide Diuretic
RETORLIX 100 Torsemide Diuretic
RETORLIX injection
Torsemide Diuretic
RETORLIX SPTorsemide + Spironolactone
Diuretic
VALENT 40 Valsartan Anti-Hypertensive
VALENT 80mg Valsartan Anti-Hypertensive
VALENT H Valsartan + Hctz Anti-Hypertensive
VALENT 160 Valsartan Anti-Hypertensive
VALENT R Valsartan +Ramipril Anti-Hypertensive
PINOM 10 Olmesartan Anti-Hypertensive
PINOM 20 Olmesartan Anti-Hypertensive
PINOM 40 MG Olmesartan Anti-Hypertensive
PINOM H Olmesartan + Hctz Anti-Hypertensive
PINOM A 20 MG Olmesartan + Amlodipine Anti-Hypertensive
CLOPITAB 75mg Clopidogrel Antiplatelet
CLOPITAB 150 Clopidogrel Antiplatelet
CLOPITAB A 75 Clopidogrel + Aspirin Antiplatelet
CLOPITAB A 150 Clopidogrel + Aspirin Antiplatelet
CILODOC 50 Cilostazol Antiplatelet
CILODOC 100 Cilostazol Antiplatelet
FAXIMAB 10MG/5 ML VIAL
Abciximabinj Antiplatelet
LUPENOX 20MG Enoxaparin Anticoagulant
LUPENOX 40MG Enoxaparin Anticoagulant
LUPENOX 60MG Enoxaparin Anticoagulant
PLANEP Eplerenone Diuretic
ISONORM 10 IsosordibeMononitrate Antianginal
ISONORM 20 IsosordibeMononitrate Antianginal
ISONORM 30 SR IsosordibeMononitrate Antianginal
IVABRAD 5MG Ivabradine Antianginal
IVABRAD 7.5MG Ivabradine Antianginal
DOFUSE Injection Dobutamine Positive Ionotropes
LUPIDIP 2.5/5/10 mg
Amlodipine Anti-Hypertensive
LUPIBOSE 62.5/125 mg
Bosentan Pulmonary Anti-Hypertensive
HARTYResveratrol + Grape seed extract
Nutritional Supplement
Pinnacle CVN (CARDIOVASCULAR NEPHROLOGY)
Brand Name Molecule Therapy Segment
ATENOVA 25 MG
Atenolol Anti-Hypertensive
ATENOVA 50 MG
Atenolol Anti-Hypertensive
ATENOVA 100 MG
Atenolol Anti-Hypertensive
EZEDOC Ezetimibe Cholesterol Reducer
FRUSELACFrusemide + Spironolactone
Diuretic
FRUSELAC DS Frusemide + Diuretic
Spironolactone
ISONORM 10 IsosordibeMononitrate Anti-Anginal
ISONORM 20 IsosordibeMononitrate Anti-Anginal
ISONORM 30 SR IsosordibeMononitrate Anti-Anginal
LIPRIL 2.5mg Lisinopril Anti-Hypertensive
LIPRIL 5mg Lisinopril Anti-Hypertensive
LIPRIL 10mg Lisinopril Anti-Hypertensive
LIPRIL AM Lisinopril + Amlodipine Anti-Hypertensive
LIPRIL HLisinorpil + Hydrochlorothiazide
Anti-Hypertensive
NEBISTAR 2.5mg
Nebivolol Anti-Hypertensive
NEBISTAR 5mg Nebivolol Anti-Hypertensive
NEBISTAR SANebivilol + s-amlodipine
Anti-Hypertensive
NEBISTAR HNebivilol + Hydrochlorothiazide
Anti-Hypertensive
STARPRESS XL 100
Metoprolol Anti-Hypertensive
STARPRESS XL 25
Metoprolol Anti-Hypertensive
STARPRESS XL 50
Metoprolol Anti-Hypertensive
STARPRESS H 25 XL
Metoprolol + Hydrochlorothiazide
Anti-Hypertensive
STARPRESS H 50 XL
Metoprolol + Hydrochlorothiazide
Anti-Hypertensive
STARPRESS AM Metoprolol + Anti-Hypertensive
XL 30 Amlodipine
STARPRESS AM XL
Metoprolol + Amlodipine
Anti-Hypertensive
STARPRESS MN XL 30
Metolprolol + Isosorbidemononitrate
Anti-Hypertensive+Anti-Anginal
STARPRESS MN XL 60
Metolprolol + Isosorbidemononitrate
Anti-Hypertensive+Anti-Anginal
STARPRESS R XL 25
Metoprolol + Ramipril Anti-Hypertensive
STARPRESS R XL 50
Metoprolol + Ramipril Anti-Hypertensive
RANCAD Ranolazine Anti-Anginal
NOVASTAT 5MG Rosuvastatin Cholesterol Reducer
NOVASTAT 10MG
Rosuvastatin Cholesterol Reducer
NOVASTAT 20MG
Rosuvastatin Cholesterol Reducer
FLETA BOLUS INJ
Eptifibatide Antiplatelet
FLETA INFUSION
Eptifibatide Antiplatelet
TIROFUSE Tirofiban Antiplatelet
LUPIFLO 7.5 LRecombinant Streptokinase
Fibrinolytic
LUPIFLO 15 LRecombinant Streptokinase
Fibrinolytic
SENACEPT Cinacalcet HCL Calcimimetic
Endeavour
Brand Name Molecule Therapy Segment
CALUFT CAPS CALCIUM CARBONATE + CALCITRIOL + ZINC + MAGNESIUM + BORON
ANTI-OSTEOPOROSIS
CALUFT-G CALCIUM CITRATE MALEATE + VIT.D3 + ZINC + MANGANESE + MAGNESIUM + COPPER
CALCIUM PREPARATION
CEFAXONE 1000 Mg
CEFTRIAXONE IM/IVANTI INFECTIVE INJECTABLE
CEFAXONE 125 Mg
CEFTRIAXONE IM/IVANTI INFECTIVE INJECTABLE
CEFAXONE 250 Mg
CEFTRIAXONE IM/IVANTI INFECTIVE INJECTABLE
CEFAXONE 500 Mg
CEFTRIAXONE IM/IVANTI INFECTIVE INJECTABLE
CEFFOREN CEFDITORENAnti-bacterial (CEPHALOSPORIN ORAL)
CO-Q-DENT CO-Q-10HERBAL TOOTHPASTE
CO-Q-DENT CO-Q-10HERBAL TOOTHPASTE
CZ-3 COLDPHENYLPROPANOLAMINE 25MG + CETIRIZINE 5MG + PARACETAMOL 500MG
COLD PREPARATION
CZ-3 SYRUP CETRIZINE ANTI-HISTAMINE
CZ-3 TABLET CETRIZINE ANTI-HISTAMINE
CZ-COLD CETRIZINE 5MG + PSEUDOEPHEDRINE 30MG/5ML
COLD PREPARATION
CZ-EX AMBROXOL 15MG + R-SALBUTAMOL 1MG + GUAIPHENESIN 50 MG + MENTHOL 0.5MG
COUGH PREPARATION
CZ-TUS DEXTROMETHORPHAN + CETRIZINE + PSEUDOEPHEDRINE + MENTHOL
COUGH PREPARATION
DOXCEF 100 CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)
DOXCEF 100 DRY SYRUP
CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)
DOXCEF 200 CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)
DOXCEF 50 DRY SYRUP
CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)
DOXCEF 50 DT CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)
DOXCEFF DT 100 MG
CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)
EUBIOZ CAP PREBIOTIC PROBIOTIC COMBINATION Gastro-intestinal
EUBIOZ SACHET
PREBIOTIC PROBIOTIC COMBINATION Gastro-intestinal
HEPP FORTE SYRUP
- HAEMATINIC
LUPIN TAZOX 250 MG
CEFTRIAXONE + TAZOBACTAMANTI INFECTIVE INJECTABLE
LUPIN TAZOX 1 GM
CEFTRIAXONE + TAZOBACTAMANTI INFECTIVE INJECTABLE
LUPINEM 500 MG IMIPENEM + CILASTATINANTI INFECTIVE INJECTABLE
MAGNOVA 1G CEFEPIME+TAZOBACTAMANTI INFECTIVE INJECTABLE
MAGNOVA 250 MG
CEFEPIME+TAZOBACTAMANTI INFECTIVE INJECTABLE
MAGNOVA 5G CEFEPIME+TAZOBACTAMANTI INFECTIVE INJECTABLE
NIZONIDE NITAZOXANIDE Anti-diarrhoeal
NIZONIDE DT TABLET
NITAZOXANIDE Anti-diarrhoeal
NIZONIDE SUSP NITAZOXANIDE Anti-diarrhoeal
NIZONIDE-O NITAZOXANIDE + OFLOXACIN Anti-diarrhoeal
NIZONIDE-O SUSP
NITAZOXANIDE + OFLOXACIN Anti-diarrhoeal
Novapime 1000 mg
CEFEPIME CEPHALOSPORIN INJ
NOVAPIME 250 MG INJ
CEFEPIME CEPHALOSPORIN INJ
Novapime 500 mg
CEFEPIME CEPHALOSPORIN INJ
ODOXIL 125 DT CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL 250 DT TABLETS
CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL 250 PREMIX
CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL 500 Mg CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL DS CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL OD CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL PREMIX CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
ODOXIL SUSPENSION
CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)
OPTINEURON INJ
VITAMIN B COMPLEX NEUROTROPIC
OPTINEURON TABS
VITAMIN B COMPLEX NEUROTROPIC
PERCIN PRULIFLOXACIN 600MGORAL ANTI-INFECTIVE
RABLET 10 MG RABEPRAZOLE Anti-peptic Ulcerant
RABLET 10 MG RABEPRAZOLE Anti-peptic Ulcerant
RABLET 20 MG RABEPRAZOLE Anti-peptic Ulcerant
RABLET 20 MG RABEPRAZOLE Anti-peptic Ulcerant
RABLET D caps RABEPRAZOLE + DOMPERIDONE Gastro-intestinal
RABLET I.V. SALES (1
RABEPRAZOLE IV Anti-peptic Ulcerant
RABLET IT RABEPRAZOLE+ITOPRIDE Gastro-intestinal
RCIFAX RIFAXIMINGI Anti-bacterial (RIFAMPICIN DERIVATIVE)
RCLONAC TABLET 10 X
DICLOFENAC SR+ RABEPRAZOLE NSAID + APU
RESNER INJ MECOBALAMINE NEUROTROPIC
RESNER SOFT CAPSULES
MECOBALAMINE NEUROTROPIC
SIGNOFLAM -P TAB
ACECLOFENAC NSAIDS
SIGNOFLAM TABLET
ACECLOFENAC NSAIDS
SOFTOVAC ISABGOL COMBINATION LAXATIVE
SOFTOVAC SF ISABGOL COMBINATION LAXATIVE
TOPCERIN DIACEREINOTHER PLAIN ANTI ARTHRITIC
ULYSES 150 MG URSODESOXYCHOLIC ACIDHEPATO-PROTECTIVE
ULYSES 300 MG URSODESOXYCHOLIC ACIDHEPATO-PROTECTIVE
VIDA-25 LOSARTAN ANTI HYPERTENSIVE
VIDA-50 LOSARTAN ANTI HYPERTENSIVE
VIDA-H LOSARTAN+HYDROCHLOROTHIAZIDE ANTI HYPERTENSIVE
Lupin Diabetes Care
Brand Name Molecule Therapy segment
Gluconorm SRMetformin 500 mg extended release
Diabetes Management
Gluconorm SR 1 g
Metformin 1 gm extended release
Diabetes Management
Gluconorm G1Metformin 500 mg ER + Glimepiride 1 mg
Diabetes Management
Gluconorm G2Metformin 500 mg ER + Glimepiride 2 mg
Diabetes Management
Gluconorm P15Metformin 500 mg ER + Pioglitazone 15 mg
Diabetes Management
Gluconorm P30Metformin 500 mg ER + Pioglitazone 30mg
Diabetes Management
Gluconorm PG-1
Metformin 500 mg ER + Pioglitazone 15 mg + Glimepiride 1 mg
Diabetes Management
Gluconorm PG-2
Metformin 500 mg ER + Pioglitazone 15 mg + Glimepiride 2 mg
Diabetes Management
Gluconorm G1 Forte
Metformin 1 gm ER + Glimepiride 1mg
Diabetes Management
Gluconorm G2-1 Forte
Metformin 1 gm ER + Glimepiride 2 mg
Diabetes Management
Glutide CR 30MG
Gliclazide Controlled Release 30 mg
Diabetes Management
Glutide CR 60MG
Gliclazide Controlled Release 60 mg
Diabetes Management
Glador 1 Glimepiride 1 mg Diabetes Management
Glador 2 Glimepiride 2 mg Diabetes Management
Glador 3 Glimepiride 3 mg Diabetes Management
Glador 4 Glimepiride 4 mg Diabetes Management
Lipril 2.5 Lisinopril 2.5 mg Diabetic Hypertension
Lipril 5 Lisinopril 5 mg Diabetic Hypertension
Lipril 10 Lisinopril 10 mg Diabetic Hypertension
Lipril AM Lisinopril 5 mg + Amlodipine 5 mg Diabetic Hypertension
Lipril HLisinopril 5 mg + Hydrochlorothiazide 12.5 mg
Diabetic Hypertension
Matilda Plus Mecobalamin 750 mcg + ALA 100 mg+ Pyridoxine 3mg + Folic aci
Diabetic Neuropathy Management
Matilda Forte Mecobalamin 1500 mcg + ALA 200 mg + Folic acid 1.5 mg + Pyri
Diabetic Neuropathy Management
Matilda AFMecobalamin 750 mcg + ALA 100mg + GLA 60 mg + Benfothiamin
Diabetic Neuropathy Management
Matilda ERMecobalamin 1500 mcg + Pyridoxine 20mg + Folic acid 5mg
Diabetic Neuropathy Management
Matilda Inj 1x1ml
Mecobalamin 500 mcg I.M./I.V. Diabetic Neuropathy Management
Misobit 25 Miglitol 25 mg Diabetes Management
Misobit 50 Miglitol 50 mg Diabetes Management
Misobit MD 25 Miglitol Mouth Dissolving 25 mg Diabetes Management
Misobit MD 50 Miglitol Mouth Dissolving 50 mg Diabetes Management
Path 15mg Pioglitazone 15 mg Diabetes Management
Path 30 mg Pioglitazone 30 mg Diabetes Management
Path G1Pioglitazone 15 mg + Glimepiride 1 mg
Diabetes Management
Path G2Pioglitazone 15 mg + Glimepiride 2 mg
Diabetes Management
Retorlix 5 Torsemide 5 mg Diabetic Hypertension
Retorlix 10 Torsemide 10 mg Diabetic Hypertension
Retorlix 20 Torsemide 20 mg Diabetic Hypertension
Retorlix 100 Torsemide 100 mg Diabetic Hypertension
Retorlixinj Torsemide Injection 10mg/ml Diabetic Hypertension
Retorlix SP 5Torsemide 5 mg + Spironolactone 50 mg
Diabetic Hypertension
Retorlix SP 10Torsemide 10 mg + Spironolactone 50 mg
Diabetic Hypertension
Starstat 5 Simvastatin 5 mg Diabetic Dyslipidemia
Starstat 10 Simvastatin 10 mg Diabetic Dyslipidemia
Starstat 20 Simvastatin 20 mg Diabetic Dyslipidemia
Starstat 40 Simvastatin 40 mg Diabetic Dyslipidemia
Starstat EZ 10 Simvastatin 10 mg + Ezetimibe Diabetic Dyslipidemia
Starstat EZ 20 Simvastatin 20 mg+ Ezetimibe Diabetic Dyslipidemia
Telista 20 Telmisartan 20 mg Diabetic Hypertension
Telista 40 Telmisartan 40 mg Diabetic Hypertension
Telista 80 Telmisartan 80 mg Diabetic Hypertension
Telista HTelmisartan 40 mg + Hydrochlorothiazide 12.5 mg
Diabetic Hypertension
Telista RM 2.5Telmisartan 40 mg + Ramipril 5 mg
Diabetic Hypertension
Telista - RM 5Telmisartan 40 mg + Ramipril 2.5 mg
Diabetic Hypertension
Telista - AMTelmisartan 40 mg + Amlodipine 5mg
Diabetic Hypertension
GABASTAR 300 Gabapentin 300 mg Diabetic Neuropathy Management
GABASTAR SR 600
Gabapentin sustained release 600 mg
Diabetic Neuropathy Management
GABASTAR MGabapentin 300 mg + Mecobalamin 500 mcg
Diabetic Neuropathy Management
GABASTAR MAX
Gabapentin 300 mg + Mecobalamin 500 mcg + ALA 100 mg
Diabetic Neuropathy Management
PREGASTAR 75 Pregabalin 75 mg Diabetic Neuropathy Management
PREGASTAR Pregabalin 150 mg Diabetic Neuropathy Management
150
PREGASTAR M 75
Pregabalin 75 mg + Mecobalamin 750 mcg
Diabetic Neuropathy Management
PREGASTAR M 150
Pregabalin 150 mg + Mecobalamin 750 mcg
Diabetic Neuropathy Management
DUMORE 20 Duloxetine 20 mg Diabetic Neuropathy Management
DUMORE 30 Duloxetine 30 mg Diabetic Neuropathy Management
DUMORE 60 Duloxetine 60 mg Diabetic Neuropathy Management
DUMORE M 20Duloxetine 20 mg + Mecobalamin 750 mcg
Diabetic Neuropathy Management
DUMORE M 30Duloxetine 30 mg + Mecobalamin 750 mcg
Diabetic Neuropathy Management
DUMORE M 60Duloxetine 60 mg + Mecobalamin 750 mcg
Diabetic Neuropathy Management
RIBAFIT Rimonabant 20 mg Diabetic Dyslipidemia
Vobit 0.2mg Voglibose 0.2 mg Diabetes Management
Vobit 0.3mg Voglibose 0.3 mg Diabetes Management
LUPSULIN N 40 Recombinant Human Insulin NPH Diabetes Management
LUPSULIN R 40Recombinant Human Insulin Regular
Diabetes Management
LUPSULIN M 30/70
Recombinant Human Insulin 30% Regular & 70% NPH
Diabetes Management
LUPSULIN M 50/50
Recombinant Human Insulin 50% Regular & 50% NPH
Diabetes Management
NOVASTAT 5 Rosuvastatin 5 mg Diabetic Dyslipidemia
NOVASTAT 10 Rosuvastatin 10 mg Diabetic Dyslipidemia
NOVASTAT 20 Rosuvastatin 20 mg Diabetic Dyslipidemia
LupinRespira
Brand Name Molecule Therapy Segment
BUDAMATE 100 TRANSCAPS(DPI)
Formoterol 6 mcg & Budesonide 100 mcg
ICS+LABA
BUDAMATE 200 TRANSCAPS(DPI)
Formoterol 6 mcg & Budesonide 200 mcg
ICS+LABA
BUDAMATE 400 INHALER(MDI)
Formoterol 6 mcg & Budesonide 400 mcg
ICS+LABA
BUDAMATE 100 INHALER(MDI)BOX
Formoterol 6 mcg & Budesonide 100 mcg
ICS+LABA
BUDAMATE 400 TRANSCAPS (DPI)
Formoterol 6 mcg & Budesonide 400 mcg
ICS+LABA
BUDAMATE 200 INHALER(MDI)BOX
Formoterol 6 mcg & Budesonide 200 mcg
ICS+LABA
BUDATE 100 DPI Budesonide 100 mcg ICS
BUDATE 100 MDI Budesonide 100 mcg ICS
BUDATE 200 DPI Budesonide 200 mcg ICS
BUDATE 200 MDI Budesonide 200 mcg ICS
BUDATE 400 DPI Budesonide 400 mcg ICS
BUDATE 4X5X2ML Budesonide.5mg per 2 ML ICS
BUDATE FORTE 4X5X2ML
Budesonide 1mg per 2ml ICS
BUDATE 3X7X2ML Budesonide.5mg per 2 ML ICS
ESIFLO 125 INHALER(MDI)BOX
Salmeterol 25 mcg & Fluticasone 125 mcg
ICS+LABA
ESIFLO 250 INHALER(MDI) BOX
Salmeterol 25 mcg & Fluticasone 250 mcg
ICS+LABA
ESIFLO500 TRANSCAPS
Salmeterol 50 mcg & Fluticasone 500 mcg
ICS+LABA
ESIFLOR 100 Salmeterol 50 mcg & Fluticasone ICS+LABA
TRANSCAPS (DPI) 100 mcg
ESIFLOR 250 TRANSCAPS (DPI)
Salmeterol 50 mcg & Fluticasone 250 mcg
ICS+LABA
FLUTIFLOFLUTICASONE 50 MCG EACH SPRAY
INCS
IPNEB 15ML Ipratropium 250 mcg/per ml ANTICHOLINERGIC
MOMEFLOmometasone 50 mcg in each spray
INCS
SALBAIR (MDI) Levo-Salbutamol 50 mcg BRONCHODILATOR
SALBAIR TRANSCAPS(DPI)
Levo-Salbutamol 100 mcg BRONCHODILATOR
SALBAIR 1 TRANSCAPS(DPI)
Levosalbutamol 100mcg+ipratropium 40 mcg
BRONCHODILATOR + ANTOCHOLINERGIC
SALBAIR 1 TRANSCAPS(DPI)
Levosalbutamol 100mcg+ipratropium 40 mcg
BRONCHODILATOR + ANTOCHOLINERGIC
SALBAIR 1 TRANSPULE
salbutamol 2,5mg+ipratropium500mcg for 2.5ml
BRONCHODILATOR
SALBAIR 15ML salbutamol 5mg/ml BRONCHODILATOR
SALBAIR B (MDI)BOX
levosalbutamol 50mcg+beclomethasone 50mcg
ICS+BRONCHODILATOR
SALBAIR B FORTE TRANSCAPS (DPI)
Levosalbutamol 100mcg+beclomethasone200mcg
ICS+BRONCHODILATOR
SALBAIR B TRANSCAPS (DPI)
levosalbutamol 100+ beclomethasone 100mcg
ICS+BRONCHODILATOR
SALBAIR I (MDI) BOX
levosalbutamol 50 mcg+ipratropium 20 mcg
ICS+ ANTICHOLINERGIC
SALBAIR TRANSCAPS (DPI)
levosalbutamol 50 mcg BRONCHODILATOR
SALBAIR TRANSPULES
salbutamol 2.5mg per 2.5 ml BRONCHODILATOR
TIATE DPI Tiotropium 18 mcg ANTICHOLINERGIC
TIATE MDI Tiotropium 9 mcg ANTICHOLINERGIC
TIOMATE DPITiotropium 18 mcg &Formoterol 12 mcg
ANTICHOLINERGIC + LABA
TIOMATE MDITiotropium 9 mcg &Formoterol 6 mcg
ANTICHOLINERGIC + LABA
AZEFLOAzelastine 140 mcg + 50 mcg fluticasone each spray
ANTIHISTAMINE+ INCS
LUPIHALER Advanced Mono Dose Device DRUG DELIVERY SYSTEM
TELEKAST 4MGMontelukast Sodium Chewable Tablets 4 mg
ANTILEUKOTRIENE
TELEKAST 5MGMontelukast Sodium Chewable Tablets 5 mg
ANTILEUKOTRIENE
TELEKAST 10Montelukast Sodium Tablets 10 mg
ANTILEUKOTRIENE
TELEKAST PLUSMontelukast 10 mg &Bambuterol 10 mg
ANTILEUKOTRIENE + BRONCHODILATOR
TELEKASTLMontelukast 10 mg &Levocetirize 5 mg
ANTILEUKOTRIENE + ANTIHISTAMINE
LUDO 120 MDI Dose Counter DOSE COUNTER
STERIO 4Methyl Prednisolone Tablets 4 mg
ORAL STEROID
STERIO 8Methyl Prednisolone Tablets 8 mg
ORAL STEROID
STERIO 16Methyl Prednisolone Tablets 16 mg
ORAL STEROID
DOXIFLO 400MG Doxofylline tablets 400 mg BRONCHODILATOR
FORMOFLO 125 MDI
Formoterol 6 mcg & Fluticasone 125 mcg
ICS+LABA
FORMOFLO 250 MDI
Formoterol 6 mcg & Fluticasone 250 mcg
ICS+LABA
FORMOFLO 100Formoterol 6 mcg & Fluticasone 100 mcg
ICS+LABA
FORMOFLO 250 Formoterol 6 mcg & Fluticasone 250 mcg
ICS+LABA
DUOMATE TRANSCAPS
Formoterol 6 mcg &Beclomathasone 200 mcg
ICS+LABA
DUOMATE FORTEFormoterol 6 mcg &Beclomathasone 400 mcg
ICS+LABA
APTIVATE 9 natural ingredients APPITIZER
LCIN 250MG Levofloxacin 250 mg tablets ANTIBIOTIC
LCIN 500MG Levofloxacin 500 mg tablets ANTIBIOTIC
LCIN A - -
STARCET 5MG Levocetirizine 5 mg tablets ANTIHISTAMINE
STARCET Alevocetirizine 5 mg+ambroxol 75 tablets
ANTIHISTAMINE + MUCOLYTIC
STARCET COLDLevocetrizine 2.5mg+paracetamol 500mg+psedoephradine 60 mg
ANTIHISTAMINE + MUCOLYTIC+ANALGESIC
LCF COUGH FORMULA
Levosalbutamol 1mg+guaiphenesin 50 mg+ambroxol 15mg/5ml
COUGH FORMULA
LCF KIDLevosalbutamol .5mg+guaiphenesin 50 mg+ambroxol 15mg/5ml
COUGH FORMULA
INCS INTRANASAL CORTICOSTEROID -
ICS INHALEDCORTICOSTEROID -
LABALONG ACTING BRONCHODILATOR
-
MARKET SHARE OF LUPIN PHRMA
Lupin Q4 & FY 2008-09 Results - Consistent Performance & Solid Growth
Q4 2008-09 Consolidated Net Profits up 64.2% at Rs. 1574 million
May 13, 2009, Mumbai, India
Leading transnational pharmaceutical major, Lupin Limited, reported an outstanding performance for the fourth quarter and financial year ended March 31st, 2009. These audited results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Key Highlights - Consolidated FY 08-09
Net sales grew at 39.5% to Rs. 37759 million from Rs. 27064 million
last year Net profit grew at 50.2% to Rs. 5015 million compared
to Rs. 3338 mn in previous year (excluding IP income) EBITDA margin increased to 19.7% Exports up by 63.2% at Rs. 24701 mn Advanced markets sales (including Japan and ANZ)
increased to 92% over last year and contributed 50% of the Net Sales for the year as against 36% in the previous year.
Advanced Markets sales to US and EU grew at 70% to Rs.14310 million including API
One of the fastest growing generic players in the US by prescriptions and the 9th largest in terms of total prescription base
A basket of 22 products in the US with 8 market leaders
Domestic Formulations Business grew at 24.6%% to Rs. 10,575 million.
Lupin’s Japanese subsidiary, Kyowa contributed 12% of the overall revenues - Rs. 4424 million
28 ANDAs, 15 DMFs, 18 MAAs,6 EDMFs,3 COS, & 1 AU DMF were filed during FY 08-09.
Four Major Acquisitions across Germany, Australia, South Africa and the Philippines
Dividend Announcement of 125 %
Key Highlights Q4 FY 08-09
Net sales for Q4 FY 08-09 grew at 39% to Rs.10434 million.
Advanced markets sales (U.S, EU & Japan) increased to 86 % at Rs 5681 million over Q4 FY 07-08
Net profit for Q4 FY 08-09 grew at 64.2% to Rs.1574 million compared to Rs. 959 million in Q4 FY 07-08
Commenting on Lupin’s performance, Dr. Kamal K Sharma, Managing Director, Lupin Limited, said, “Lupin’s stellar performance reflects the strong business philosophy guiding us. Lupin has had a very strong year driven by growth and consistent performance across all business segments and markets: a strong business performance in the US, solid domestic growth & increased activity in all key markets. Lupin’s acquisitions have not only consolidated our existing presence in these markets but also leaves us strategically poised to further strengthening our position in the global generics and branded generics market. It has indeed been a year of many achievements and robust growth, and we are now strategically poised to not only address market needs but also maintain momentum and direction.”
Financials:
Advanced markets – US & Europe
Lupin continued its growth momentum in the US and Europe a healthy contribution of 36% to our total revenues at Rs. 13634 million. (Formulations)
USA:
Lupin Pharmaceuticals Inc., the company’s US subsidiary, reported a stellar performance recording sales of Rs. 12563 million reflecting a growth of 74.4% as compared to Rs. 7205 million in FY 07-08. Lupin’s Generic and Branded business recorded exponential growth during the financial year.
More importantly, FY 08-09 saw Lupin increasing its product portfolio in the branded generics segment through the launch of AeroChamber Plus®. LPI forged a Strategic Alliance with Forest Laboratories, Inc. for marketing and promoting AeroChamber Plus® thereby extending Lupin’s presence in the respiratory segment and our franchise with Pediatricians which would also additionally open up new offices for Suprax. The brand business contributed 27% to the overall business at USD 74 mn
The company further expanded and consolidated on its generic product portfolio with the launches of Ramipril caps, Divalproex DR tabs, Cefadroxil suspension and caps &Levetiracetam tabs. The Company now has a total of 22 products in the market, out of which 8 are market leaders. We are in the top 3 market positions by market share in 17 of these products (IMS Jan 09).
Lupin today is one of the fastest growing generic players in the US based on growth in prescriptions and the 9th largest in terms of total prescription base.
LPI was also recognized by Wal-Mart and awarded its prestigious “Supplier Award of Excellence” for the 2nd Quarter 2008 – which is an acknowledgement of the inroads we have made into the US markets.
During the year, the company demonstrated its capabilities on the Intellectual Property management front by successfully litigating and settling all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough’s "Clarinex"® tablets. As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances. Schering-Plough’s Clarinex® tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.
Lupin also received the final approval for the Company’s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have commenced.
Lupin’sLevetiracetam tablets are the AB-rated generic equivalent of UCB Pharmaceuticals’ Keppra® tablets, indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy. Keppra tablets had annual sales of approximately $ 1.2 billion (USD) for the twelve months ended September 2008, based on IMS Health sales data.
Europe:
Lupin further strengthened its presence in the European Union by completeing its acquisition of HormosanPharma GmbH (Hormosan), a German generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS).
We also recorded our first strategic win in the German market through Hormosan in the next two quarters – having received information on the results of the AllgemeineOrtskrankenkassen (AOK) Tender, pursuant to § 130a SGB V. Hormosan has been offered to supply Setraline in all 5 regions of Germany covering all AOK-insured persons.
Hormosan has a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector.
Lupin also made strategic inroads into the French market by launching CefpodoximeProxetil suspension in Q3. CefpodoximeProxetil has over 60 % market share in France.
AAMLA
Japan:
Kyowa, the Company’s subsidiary in Japan posted robust net sales of Rs. 4424 mn contributing 12% of Lupin’s Revenues having grown at over 21 % YoY
Our products like Amlodipine “Amel” continues to maintain majority market share and Risperidone “Amel”, which was launched last year, continue to exhibit market leadership in unit terms.
South Africa
Lupin clocked in revenues of Rs 919 million after having acquired an equity stake in Pharma Dynamics (PD) in South Africa in September 08. Pharma Dynamics is one of the fastest growing generic companies in South Africa growing at around 30 % for FY 08-09 with a clear leadership in the cardiovascular segment.
PD is ranked number 6 amongst generic companies in South Africa. The South African Generics Market is currently valued at close to 800 Million USD and growing rapidly
Phillipines
In March 2009 the Company acquired a majority stake in MulticarePharmaceuticals Phillipines, Inc. (MC) in Phillipines. MC is a premium branded generics company with a strong position in women’s health and child care segment.
ANZ
The Company continued its focus on this important market with aggressive filings in Australia, taking the cumulative MAA filings to 24 till date of which 18 have been approved.
Emerging Markets
India
Domestic Formulations forms a very important part of Lupin’s overall growth. In the current financial year, it contributed about 28% of the net sales at Rs 10,575 million as against Rs. 8,487 million registering a growth of 24.6% over the previous year.
This growth was driven by the good performance in the CVS, Diabetes, CNS, Asthma and Gastro therapy Segments. The
divisions catering to branded segments continued to outpace the industry growing over 27%. Lupin has maintained its leadership in Anti-TB segment and has secured a double digit market share in the anti-asthma market riding high on the strengths of its offering in this segment.
Research and Development
Research & Development has always been a strategic and key focus area for Lupin and this year – 2008-09 was no exception with 6% of the sales earmarked for R&D and related spends.
The year 2008-09 was a landmark year with Lupin filing 28 Abbreviated New Drug Application (ANDA) with the USFDA, 11 DMFs, 15 MAAs and two EDMFs during the year.
The cumulative ANDA filings stood at 90 with 34 approvals granted by the USFDA.
Lupin also received the final approval for the Company’s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S. Food and Drug Administration (USFDA) during the quarter.
Other
The USFDA issued a warning letter for the Cephalosporin facility of the Mandideep plant. The facility was inspected in November, 2008 for a routine GMP inspection. As a result Lupin had received 15 procedural observations. Lupin responded to the observations in December and provided corrective actions for each of the responses.
The warning letter was issued to provide Lupin with an opportunity to submit additional documentation and explanation to a few selected observations where the FDA
felt that the initial responses were inadequate and could be strengthened by further evidence of compliance with enhanced documentation practices.
All products maintain their approved status. Lupin manufacturing will not be disrupted and it will continue to provide quality products to customers without interruption.
Lupin has formulated a strategy to address and resolve the USFDA and is confident of being able to satisfy the USFDA’s observations expeditiously.
Dividend-In view of excellent performance, the Board of Directors recommended a dividend of 125 % i.eRs. 12.50 per equity share of the face value of Rs. 10 each.
COMPANY MANUFACTURING/R&D
Business Development
Lupin was founded to meet the very basic need for effective treatment of tuberculosis. Our success is tied to continually meeting the need for basic products to promote human health. Our company strives to bring important new products to market each year. We expect our products to come from:
In-house product development; Licensing and acquisitions; Marketing alliances.
Lupin is also seeking to be the partner of choice for product development. Our scientists apply know how and expertise to develop NCE’s or to solve difficult formulation challenges.
We strive for continued growth and are avidly interested in learning about prospective opportunities in the specialty pharmaceutical market. We are also open to collaborating to develop innovative products formulated with Lupin’s drug delivery and taste masking
technology. Our API business unit is seeking partners for Lupin developed API's.
Please contact us regarding business or product collaboration opportunities
Phone: 410-576-2000
Facsimile: 410-576-2221
Email: [email protected]
NEW Products
Generics
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil. Since then we have received more than a dozen FDA approvals. Six of Lupin's 14 ANDA approvals were the first granted by the US FDA, reinforcing our ability to submit high quality dossiers and gain on time approvals.
We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive
prices.
Our integrated manufacturing capability provides a portfolio of the highest quality generic products.
Expanding the product portfolio, Lupin Pharmaceuticals, Inc. is geared to file 15 or more ANDA’s per year in some of the following areas:
Oral and injectable cephalosporins;Cardiovascular;Controlled release ANDA’s;Paragraph IV’s.
Our oral and injectable cephalosporin facilities, US FDA approved manufacturing sites and the new tablet and capsule facility in Goa, allow us to file and manufacture a wide range of finished products for the US market.
Newsroom
Lupin receives FDA approval for Imipramine Pamoate Capsules
View
Apr 16, 2010
Lupin receives FDA tentative approval for Eszopiclone tablets
View
Mar 20, 2010
Lupin receives FDA approval for Amlodipine/Benazepril capsules
View
Feb 08, 2010
Lupin receives FDA approval for Perindopril Erbumine Tablets
View
Jan 28, 2010
Lupin receives FDA tentative approval for MemantineHCl tablets
View
Jan 19, 2010
Lupin is granted USFDA approval for Levetiracetam Tablets
View
Jan 16, 2009
Lupin Receives “Supplier Award of Excellence” from Wal-Mart
View
Sept 17, 2008
Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets
View
July 29, 2008
Lupin appoints New NCE Research Head. June 26, 2008
View
Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U.S.
View
June 23, 2008
Lupin receives USFDA approval for Escitalopram Oxalate Tablets
View
June 16, 2008
Lupin launches Ramipril capsules
View
June 10, 2008
Lupin receives USFDA approval for Topiramate Tablets
View
May 29, 2008
Lupin Receives “Best New Manufacturer of the Year” Award from AmerisourceBergen
View
July 30, 2007
Lupin receives final approval for Amlodipine Tablets
View
July 12, 2007
Lupin announces Final Approval of Trandolapril Tablets June 13,
View
2007
Lupin Receives US FDA Approval for ZiprasidoneHCl Capsules
View
May 22, 2007
Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension, 250 mg/5 mL, Launches Entire Product Family.
View
May 8, 2007
Lupin Receives US FDA Approval for Novel Formulation of Suprax® Suspension
View
April 12, 2007
Lupin Receives US FDA Approval for Sertraline.
View
February 7, 2007
Products
Specialty
A commitment To Caring For Kids
Lupin Pharmaceuticals, Inc. is committed to developing a branded pharmaceutical presence for pediatric practice in the US market. We are committed to identifying, developing and marketing prescription drugs for children of all ages. Lupin has created a dedicated national sales force to call upon pediatricians.
Lupin Pharmaceuticals, Inc., is very pleased to offer Suprax®, an important anti-infective product in pediatric and other physician practices within the United States. Suprax® is now available in tablets and suspension formulations. Lupin Pharmaceuticals, Inc., has an exclusive license in the United States to use the Suprax® trademark.
We plan to expand our family of pediatric products to help meet needs of children. Our focus is on in-house product development with our proprietary oral controlled release and taste masking platforms. Lupin Pharmaceuticals, Inc. is also open to marketing alliances, and to licensing/acquisitions.
API
Lupin is recognized as a leading manufacturer of cephalosporin API’s, with FDA approval to manufacture complex oral and injectable cephalosporins.Lupin is fast gaining share in the cardiovascular segment manufacturing a wide range of ACE-inhibitors and cholesterol reducing agents.Lupin’s capabilities in sterile processing, synthetic process development and fermentation skills coupled with its intellectual property strengths, puts the company in a very strong position to offer a diverse portfolio of niche API’s to its customers.
SHARE IN MARKET ANNUL
Lupin Limited (NSE:EQLUPIN)
Lupin Limited is amongst the top six pharmaceutical companies in India in terms of revenue. The Company is the world’s largest manufacturer of Tuberculosis drugs.
Business Overview
Headquartered in Mumbai, India Lupin Limited is a transnational pharmaceutical company producing generic and branded formulations and Active Pharmaceutical
Ingredients(APIs)[1]The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs(Non-steroidal anti-inflammatory drugs)[1]
Net profit for Q4 FY 08-09 grew at 64.2% at Rs. 1574 million compared to Rs 959 million in Q4 FY 07-08.Net sales growth for Q4 FY 08-09 was 39% at Rs. 10434 million.[1]
Business and Financial Metrics
Lupin Limited's share holding pattern [4]Entity Percentage
Indian Promoters 50.62%Foreign Promoters 0.01% FII's 11.15% General Public9.21%Banks Fin. Inst. and Insurance09.76%Private Corporate Bodies1.48%NRI's/OCB's/Foreign Others2.90%Others0.13%
Business Segments
Formulations Active Pharamceutical Ingredients and Intermediates ROCE is comparable to the best in the segment at 33%[6]
\
Competition
The pharmaceutical industry is characterized by rapid advances in scientific knowledge and ability to discover new drugs.The industry is therefore led by large manufacturers and marketers of drugs investing heavily in research & development, having clinical testing, marketing and distributing capabilities[7].Some of the main competitors of Lupin are:
Sun PharamceuticalsIndustires - It is No. 1 in India in speciality therapy areas like
psychiatry, neurology, cardiology, gastroenterology, diabetology and respiratory. [8].It has
brands in 30 markets worldwide and also has a generic presence in the U.S. with Caraco
Pharm Labs, Sun Pharmaceutical Industries Inc (subsidiary)[8]
Cipla - Cipla is a leader in the domestic retail pharmaceutical market. [9]It also exports raw
materials, intermediates, prescription drugs, over-the-counter products, and veterinary
products to some 180 countries around the world.[9]
GlaxoSmithKline - It is one of the oldest pharma companies in India and with a turnover of
Rs. 1500 crore is one of the market leaders(market share) in India with a share of 6.2 per
cent[10]Its main portfolios consists of anti- infectives, dermatologicals and pain management
drugs[11]
Dr. Reddy's Laboratories - It is a global pharmaceutical company with it's headquarters in
India and a presence in more than 100 countries.[12]In India it the biggest drug maker by
sales[13]
Comparison with the competitors:
Financial metrics FY2008
Name Yr Ended Market Capitalization in Rs Cr Sales Turnover in Rs Cr Net Profit in Rs Cr
Mar '08 6,473.42 2,661.62 443.38
Sun Pharma Mar '08 26,975.87 2,427.35 1,014.04
Mar '08 17,947.66 4,293.95 701.43
GlaxoSmithKlinDec '07 9,992.41 1,762.64 576.57
DrReddys Labs Mar '08 9,662.53 3,428.40 475.22
Market Share on the basis of Retail Sales Due to high level of fragmentation none of the
Pharma Companies had more than 6% of the total market on the basis of the total retail sales. [15]
KEY DEVELOPMENTS FOR LUPIN PHARMACEUTICALS, INC.Lupin Pharmaceuticals, Inc. Gets US FDA Nod for Anti-Depressant
04/20/2010
Lupin Pharmaceuticals, Inc. announced that it has been granted final approval from the Food and Drug Administration (FDA) for the capsules in strengths of 75 mg, 100 mg, 125 mg and 150 mg. The drug is recommended for relieving depression symptoms. Lupin's Imipramine Pamoate capsules are generic equivalent of Mallinckrodt's Tofranil-PM. The drug had an annual sales of about $39 million for the year ended December, 2009.
Lupin Receives FDA Tentative Approval for Eszopiclone Tablets
03/22/2010
Lupin Pharmaceuticals, Inc. announced that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration (USFDA). The company's Eszopiclone tablets are the AB-rated generic equivalent of Sepracor's LUNESTAR tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761 million for the twelve months ended